Diagnosis of Fabry Disease: Impact of an Educational Brochure Intended for Cardiologist

NCT02883205 | Unknown

• 1 other identifier: 15-060
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The cardiac Fabry disease are early, frequent and severe, dominated by the frequency of left ventricular hypertrophy. They are responsible for a high morbidity and mortality, reducing life expectancy of 15 to 20 years for men. Fabry disease and heart attacks are still diagnosed late. This delay in diagnosis is due to the non-specificity of clinical, electrocardiographic and echocardiographic disease, but also by a certain ignorance of this pathology in the medical community. The importance of early diagnosis of Fabry disease and heart disease is well established: enzyme replacement therapy is most effective when instituted early, before the onset of irreversible damage such as fibrosis. With the blotter, we now have a simple and robust screening tool for Fabry disease, achievable consultation. Targeted educational interventions to physicians have shown their effectiveness in improving the screening and diagnosis of rare diseases. We offer a prospective observational type before / after study, which aims to assess the value of an educational brochure for cardiologists to improve the screening and diagnosis of Fabry disease in Normandy.

Conditions

Cardiomyopathies

Outcome Measures

Primary Outcomes (1)

• Number of new cases of Fabry disease diagnosed a year after distribution of educational brochure cardiologists

  1 year

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient with left ventricular hypertrophy of unknown etiology or of sarcomeric MHC pace, followed in Normandy, has given its consent to the search of Fabry disease

You may qualify if:

• Patient with left ventricular hypertrophy of unknown etiology or of sarcomeric MHC pace, followed in Normandy, has given its consent to the search of Fabry disease

You may not qualify if:

• Patients under 18 years patient refusal to participate in the study. Lack of consent to the search of Fabry disease

Sponsors & Collaborators

• University Hospital, Caen: lead

Study Sites (1)

Fabien

Caen, 14033, France

RECRUITING

MeSH Terms

Conditions

Cardiomyopathies

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Study Officials

• Fabien Labombarda, MD

  Caen HU

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Fabien Labombarda, MD

CONTACT

611238306; labombarda-f@chu-caen.fr

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 25, 2016
• First Posted: August 30, 2016
• Study Start: January 1, 2015
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: August 30, 2016

Record last verified: 2016-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)